1

Introduction
 2

Diseases
Anthrax

Pathogen

Bacillus anthracis is a Gram-positive, rod-shaped bacterium. It appears as

large, square-ended rods (bacilli) under the microscope. These bacteria are
typically 1-1.2 micrometers in width and 3-5 micrometers in length. B. anthracis is
encapsulated, with a protective capsule made of poly-D-glutamic acid, which
contributes to its virulence. One of the most critical features of Bacillus anthracis
is its ability to form endospores under adverse conditions, such as exposure to
oxygen, heat, or other environmental stresses. These spores are highly resistant
and can survive for long periods in the environment, allowing the bacterium to
persist and cause infection. Bacillus anthracis produces several toxins, including
protective antigen (PA), edema factor (EF), and lethal factor (LF), which
collectively contribute to the pathogenesis of anthrax. The toxins disrupt cellular
functions and immune responses, leading to tissue damage and disease
progression.

Anthrax is primarily contracted through exposure to B. anthracis spores.

Once in the body, the spores germinate into vegetative cells, which release
toxins and multiply rapidly. The toxins produced by B. anthracis can disrupt host
cell signaling pathways, leading to cell death and tissue damage. The protective
 3

antigen (PA) component of the toxin binds to host cells, facilitating the entry of
edema factor (EF) and lethal factor (LF) into cells, where they exert their toxic
effects. In cutaneous anthrax, spores enter through breaks in the skin, germinate
locally, and produce toxins that cause ulcerative lesions. Inhaled spores can lead
to inhalational anthrax, where the bacteria are transported to the lymph nodes
and bloodstream, causing systemic disease.

The primary target cells of Bacillus anthracis are macrophages and

dendritic cells. B. anthracis spores are phagocytosed by these cells but are
capable of surviving and germinating within them due to the bacterium's ability to
evade the immune system. Bacillus anthracis evades the immune system
through various mechanisms, including its ability to produce a protective capsule
that inhibits phagocytosis, as well as the action of its toxins, which interfere with
immune cell function and signaling pathways. The ability of B. anthracis to form
spores also contributes to its persistence in the environment and resistance to
immune responses.

Reservoir
The natural reservoirs of Bacillus anthracis are animals, particularly
herbivores such as cattle, sheep, and goats. Anthrax spores can persist in the
soil for decades in regions where infected animals have died. Animals become
infected by grazing on contaminated soil or vegetation, leading to further
transmission to humans through contact with infected animal products or
carcasses. Therefore, the primary reservoirs for Bacillus anthracis are animals in
endemic regions where anthrax is prevalent.

Portal of Exit

Anthrax, caused by the bacterium Bacillus anthracis, manifests in different

forms depending on the route of entry into the body. The most common forms
are cutaneous, inhalational, and gastrointestinal anthrax, each with distinct
portals of exit facilitating the spread of the pathogen from the infected host to
others in the environment.
Cutaneous anthrax, accounting for about 95% of anthrax cases
worldwide, is characterized by the entry of B. anthracis spores through the skin,
typically via cuts or abrasions. The portal of exit in cutaneous anthrax is through
the skin itself, specifically through the open sore or lesion (ulcer) that develops at
the site of infection. As the infection progresses, Bacillus anthracis may exit the
host through the skin lesion, shedding into the environment and potentially
contaminating surfaces or materials. Transmission to others can occur through
direct contact with the infected skin lesion or through contact with contaminated
items such as clothing or bedding.
Inhalational anthrax is the most lethal form of the disease and occurs
when B. anthracis spores are inhaled into the lungs, where they can germinate
and cause severe respiratory infection. As the infection progresses, the portal of
exit shifts from the lungs into the bloodstream (bacteremia). Bacillus anthracis
 4

can then exit the host through respiratory secretions, such as coughing, thereby
disseminating the bacteria into the environment and posing a significant risk of
transmission to others through inhalation.
Gastrointestinal anthrax is the rarest form and results from consuming
contaminated meat. The portal of exit in this form of anthrax is through the
gastrointestinal tract, as the bacteria exit the host via feces during the course of
the infection. This mechanism allows for potential contamination of the
environment, posing a risk of transmission to others through contact with infected
fecal matter or contaminated food and water sources.

Mode of Transmission
Anthrax is a bacterial infection caused by Bacillus anthracis, and contrary
to common misconceptions, it is not contagious among humans. This means that
anthrax does not spread from person to person like a cold or flu virus. Instead,
transmission to humans typically occurs through direct contact with infected
animals or their products, or by inhaling or ingesting spores from contaminated
materials.
One of the primary modes of transmission is direct contact with infected
animals or their products. For instance, individuals can contract cutaneous
anthrax through direct contact with infected animal hides, wool, meat, or bones,
especially from livestock such as cattle, sheep, and goats. Handling these
materials without proper protection can lead to infection.
Inhalational anthrax is another mode of transmission where individuals
inhale airborne spores of Bacillus anthracis. This occurs through exposure to
contaminated animal products like hides, wool, or hair, or it can result from
intentional release of anthrax spores in a bioterrorism event, emphasizing the
importance of biosecurity measures.
Gastrointestinal anthrax can occur when individuals consume
contaminated meat from infected animals. Ingesting undercooked or raw meat,
particularly from herbivorous animals containing viable anthrax spores, can lead
to gastrointestinal infection.
Indirect contact transmission is also possible through exposure to
contaminated soil or surfaces harboring Bacillus anthracis spores. Inadvertently
touching contaminated materials or surfaces and then transferring the spores to
the mouth, nose, or eyes can result in infection.

Portal of Entry

Anthrax, caused by Bacillus anthracis, manifests in various forms

depending on how the bacterium enters the body. Understanding the different
portals of entry is crucial in comprehending the diverse clinical presentations of
this infectious disease.
The most common form of anthrax, cutaneous anthrax, occurs when
Bacillus anthracis spores enter through breaks in the skin. This typically happens
 5

when individuals come into direct contact with contaminated animal products or
soil. The spores then germinate locally in the skin, leading to localized infection
characterized by the development of distinctive skin lesions known as eschars.
Inhalational anthrax, considered the deadliest form, occurs when
individuals inhale Bacillus anthracis spores into their lungs. This mode of entry is
often associated with exposure to contaminated air or aerosols containing
spores. Once inside the lungs, the spores can germinate, leading to severe
respiratory infection and potentially life-threatening complications.
Gastrointestinal anthrax results from the ingestion of contaminated meat
containing viable Bacillus anthracis spores. Despite the acidic environment of the
stomach, these spores can survive and germinate in the intestines, causing
gastrointestinal infection and associated symptoms.
A newer and relatively rare form of anthrax, injectional anthrax, has been
identified among heroin-injecting drug users, particularly in northern Europe. This
unique mode of entry occurs when Bacillus anthracis spores contaminate illicit
drugs, such as heroin, and are subsequently injected into the body. Cases of
injectional anthrax highlight the adaptability of Bacillus anthracis to
unconventional routes of transmission.

Incubation Period

Depending on the mode of exposure and spore dose, the incubation

period for anthrax can vary from a few hours to several days. The most prevalent
and deemed least hazardous type of anthrax infection is cutaneous anthrax.
Usually, an infection appears one to seven days following exposure. It is thought
that inhaling anthrax is the most lethal form of the disease. After exposure,
infection often appears a week later, although it might take up to two months.
Rare cases of gastrointestinal anthrax have been documented in the US.
Usually, an infection appears one to seven days following exposure.

Susceptible Host

Anthrax infections in humans are closely linked to specific occupations

that involve frequent contact with infected animals or their products. Livestock
farmers and ranchers, for example, are at risk of anthrax due to their close
interaction with animals like cattle, sheep, and goats, which can harbor Bacillus
anthracis spores in their environment. Handling contaminated animal hides, wool,
or meat during farming and processing activities can lead to exposure and
potential infection with anthrax. Similarly, abattoir workers face occupational
hazards when slaughtering and processing animals, as they come into direct
contact with animal carcasses and tissues that may be contaminated with
anthrax spores.

Clinical Manifestations
 6

Anthrax, caused by the bacterium Bacillus anthracis, presents in various

forms depending on the route of entry into the body. Understanding these distinct
types of anthrax infections is essential for prompt diagnosis and appropriate
management.
Cutaneous anthrax is the most common and mildest form of the disease,
typically contracted through direct contact of spores with cuts, abrasions, or other
skin openings. This infection manifests initially as a raised, itchy bump
resembling an insect bite. Within a day or two, the bump transforms into a
painless sore with a characteristic black center known as an eschar. Other signs
and symptoms may include swelling in the sore and nearby lymph glands, along
with possible flu-like symptoms such as fever and headache. With appropriate
treatment, cutaneous anthrax is seldom fatal, underscoring the importance of
early recognition and medical intervention.

Gastrointestinal anthrax results from consuming undercooked meat

contaminated with Bacillus anthracis spores. This infection affects the
gastrointestinal tract from the throat to the colon. Symptoms of gastrointestinal
anthrax include nausea, vomiting, abdominal pain, headache, loss of appetite,
fever, and in later stages, severe, bloody diarrhea. Additional manifestations may
include a sore throat, difficulty swallowing, and a swollen neck. Gastrointestinal
anthrax can be severe and requires prompt medical attention to prevent
complications.
 7

Inhalation anthrax, the deadliest form of the disease, occurs when

individuals inhale Bacillus anthracis spores. Initial symptoms resemble flu-like
illness, including sore throat, mild fever, fatigue, and muscle aches. As the
infection progresses, symptoms worsen and may include chest discomfort,
shortness of breath, nausea, coughing up blood, painful swallowing, high fever,
and ultimately, severe respiratory distress leading to shock and meningitis.
Inhalation anthrax is often fatal, even with aggressive medical intervention,
making early diagnosis and treatment critical.
 8

A newer and rare route of anthrax infection, injection anthrax, has been
identified primarily among heroin-injecting drug users in Europe. This unique
form of anthrax is contracted through injecting contaminated drugs, leading to
redness, significant swelling at the injection site, shock, multiple organ failure,
and meningitis. Injection anthrax underscores the adaptability of Bacillus
anthracis to unconventional transmission routes and highlights the importance of
public health measures in addressing emerging infectious disease risks.

Diagnostic Examination
Diagnosing anthrax requires a combination of clinical evaluation,
laboratory testing, and imaging studies to confirm the presence of Bacillus
anthracis infection and determine the specific type of anthrax infection. Various
tests and procedures are employed based on the suspected route of exposure
and the clinical presentation of the disease.
For cutaneous anthrax, which is the most common form, skin testing plays
a crucial role. A sample of fluid from a suspicious skin lesion or a small tissue
biopsy may be collected and examined in a laboratory for signs of Bacillus
anthracis infection. This testing helps confirm the diagnosis and guides
appropriate treatment decisions.
Blood tests are also essential in diagnosing anthrax. A small amount of
blood is drawn and analyzed in the laboratory to detect the presence of anthrax
bacteria or their toxins. Blood cultures and specific antibody tests can provide
valuable information to support the diagnosis of anthrax and differentiate it from
other infections.
In cases of suspected inhalation anthrax, imaging studies such as chest
X-rays or computed tomography (CT) scans are instrumental. These imaging
modalities can reveal characteristic findings such as widened mediastinum (the
 9

space in the chest between the lungs), pleural effusion (fluid around the lungs),
or other signs of respiratory involvement that suggest inhalational anthrax.
Gastrointestinal anthrax can be diagnosed through stool testing. A sample
of stool is examined in the laboratory to detect the presence of Bacillus anthracis
spores or toxins, confirming gastrointestinal involvement. This test is crucial in
cases where patients present with gastrointestinal symptoms after consuming
contaminated meat.
In cases where systemic anthrax is suspected (any form of anthrax other
than cutaneous), a spinal tap or lumbar puncture may be recommended. This
procedure involves inserting a needle into the spinal canal to withdraw a small
amount of cerebrospinal fluid (CSF). A spinal tap is important to rule out
meningitis, a serious complication of anthrax that can occur with systemic
dissemination of the bacteria.

Management and Treatment

Physicians can treat anthrax patients with a variety of treatments, such as

antitoxin and antibiotics. Serious anthrax cases require hospitalization of the
patients. Aggressive treatment may be necessary for them, including ongoing
fluid drainage and mechanical ventilation to assist with breathing.
Antibiotics such as (ciprofloxacin), including intravenous antibiotics, can
be used to treat any kind of anthrax infection (medication delivered through the
vein). It is crucial to seek medical attention as soon as possible if someone
exhibits anthrax symptoms in order to maximize the likelihood of a full recovery.
Based on the patient's medical history and the best antibiotics for treating
anthrax, doctors will choose these treatments.
Antitoxin such as (valortim),anthrax bacteria can become "activated"
when spores of the disease enter the bloodstream. Once this happens, the
bacteria can proliferate, move throughout the body, and release toxins, or
poisons. Severe sickness is brought on by anthrax toxins in the body.
Antitoxin is one therapeutic treatment once the body has been exposed to
anthrax toxins. Antitoxins work against the body's anthrax toxins. Antitoxin must
be used by doctors in conjunction with other forms of therapy.
There are currently a few different kinds of antitoxins that can be used to
treat anthrax.

Prognosis

Anthrax presents different prognoses based on the type of infection and

the timeliness of treatment. Cutaneous anthrax, the most common form,
generally has a favorable prognosis when promptly diagnosed and treated with
antibiotics. The characteristic skin lesions of cutaneous anthrax, though initially
 10

alarming, respond well to antibiotics such as ciprofloxacin or doxycycline, leading

to complete recovery in the vast majority of cases.
Inhalation and gastrointestinal anthrax pose more serious risks and can be
life-threatening without timely intervention. Inhalation anthrax, caused by inhaling
Bacillus anthracis spores, can progress rapidly to severe respiratory distress and
systemic infection. Similarly, gastrointestinal anthrax, acquired through
contaminated food, can lead to profound gastrointestinal symptoms and systemic
illness. Both forms of anthrax require aggressive treatment with intravenous
antibiotics and supportive care to improve outcomes. Early recognition,
appropriate antibiotic therapy, and intensive medical management are critical in
mitigating the severity and mortality associated with inhalation and
gastrointestinal anthrax infections.

Infection Prevention and Control Measures

Preventing and controlling the spread of Bacillus anthracis, the bacterium

responsible for anthrax, requires a comprehensive approach that addresses its
specific modes of transmission and the potential risks associated with exposure.
Anthrax can infect humans through spore exposure via inhalation, ingestion, or
contact with contaminated materials. To effectively mitigate these risks, several
essential measures must be implemented.
Firstly, personal protective equipment (PPE) plays a critical role in
preventing exposure to Bacillus anthracis. Healthcare workers and individuals at
risk of exposure should wear appropriate PPE, including gloves, masks
(especially respirators if aerosol exposure is possible), gowns, and eye
protection. This is particularly important during the handling of potentially
contaminated materials, infected animals, or when caring for individuals infected
with anthrax.
Vaccination against anthrax is another crucial preventive measure,
especially for individuals at high risk of exposure such as veterinarians,
laboratory workers, and military personnel. Routine vaccination of at-risk
populations can provide immunity and significantly reduce the likelihood of
infection.The anthrax vaccine is recommended for certain groups of adults aged
18 to 65 who are at risk of anthrax exposure due to their occupational activities.
This includes laboratory workers handling anthrax, veterinarians working with
animals or animal products, and members of the military. These individuals
should receive a series of 5 shots of the anthrax vaccine over 18 months to
establish immunity against anthrax. To maintain protection, annual booster shots
are recommended thereafter. The vaccine is administered via intramuscular
injection. Pregnant women, individuals with a history of serious allergic reactions
to the anthrax vaccine or its components, and those with severe allergies
(including latex allergies) should not receive this vaccine. Additionally, individuals
with moderate or severe illnesses should consult their doctor about vaccination
timing based on their health status.
Environmental controls are essential to limit the spread of Bacillus
anthracis. Implementing strict protocols for decontamination and disinfection of
 11

surfaces, equipment, and environments where the bacterium may be present is

necessary. The use of appropriate disinfectants known to be effective against
Bacillus anthracis spores is vital for preventing environmental contamination and
subsequent transmission.
Isolation and quarantine measures are important components of
anthrax control. Infected individuals should be isolated to prevent further spread,
while potentially exposed individuals should be quarantined and monitored for
symptoms to prevent secondary cases.
Public health surveillance systems are critical for detecting and
responding to anthrax outbreaks promptly. Robust monitoring of animal
populations, particularly in agricultural settings where anthrax can affect
livestock, is essential for early detection and intervention.
Education and training initiatives are fundamental for raising
awareness about anthrax symptoms, transmission routes, and preventive
measures among healthcare workers, laboratory personnel, veterinarians, and
the general public. Proper education and training ensure that individuals
understand and adhere to proper handling, disposal, and reporting procedures
related to suspected anthrax cases.
Control measures in livestock, such as implementing vaccination
programs in endemic areas and monitoring and reporting animal deaths
suspected to be due to anthrax, are essential to prevent transmission to humans.
Regulatory measures, including enforcing regulations on the import,
export, and handling of potentially contaminated materials and animal products,
as well as ensuring compliance with biosecurity standards in laboratories and
research facilities, are imperative for preventing and controlling anthrax
outbreaks and minimizing the risk of exposure to Bacillus anthracis.

Health Education
Educating patients about preventing Bacillus anthracis infection (anthrax)
is crucial for empowering them to take proactive steps in safeguarding their
health.
It's crucial to educate patients about the various ways anthrax can be contracted
to increase awareness and facilitate preventive actions. Anthrax is primarily
contracted through exposure to spores of the bacterium Bacillus anthracis. The
most common routes of exposure include cutaneous anthrax, which occurs
through direct contact with spores on the skin, often when handling infected
animal products such as wool, hides, or meat from infected animals. Even minor
cuts or abrasions on the skin can allow the spores to enter and cause infection.
Inhalational anthrax occurs when spores are inhaled into the lungs, typically from
contaminated dust or aerosols containing anthrax spores, particularly in settings
where animal products or materials contaminated with anthrax are disturbed.
Lastly, gastrointestinal anthrax can result from consuming undercooked or raw
meat from infected animals containing anthrax spores that survive the cooking
process. By understanding these routes of exposure, patients can take
preventive measures such as avoiding direct contact with infected animals or
 12

contaminated animal products, practicing good hygiene, and adhering to

recommended vaccination schedules for individuals at high risk of exposure.

Diseases
Botulism

Pathogen
A toxin generated by the bacterium Clostridium botulinum is the cause of
the deadly disease botulism. These bacteria are frequently found in a variety of
settings, including dust and soil. Both wound contamination and the consumption
of food tainted with the toxin can result in botulism. Foodborne, newborn, wound,
and botulism linked to medication usage are among the several forms of the
disease.

Portal of Exit
Intentional exposure to aerosolized botulinum toxin is usually linked to
inhalational botulism, which is an extremely rare occurrence. In these situations,
the poison enters the body by inhalation and can pass past the lungs into the
bloodstream. Another way to get rid of the toxin is through respiratory secretions.

Mode of Transmission
The most prevalent type of botulism is foodborne botulism. It happens
when people eat food tainted with botulinum toxin, which is made by C.
microorganisms known as botulinum. Foods that have been inadequately
processed, kept, or stored are usually considered contaminated. Rarely, the
bacteria and its toxin can be found in homemade canned goods, fermented
seafood, and other preserved foods. Botulism transmission: food, wound, infant,
inhalation.

Portal of Entry
Transmission of Wound: C. Wounds and injuries, especially those polluted
with dirt or organic waste, are potential entry points for botulinum spores into the
body. Instances comprise of puncture wounds, surgical incisions, and injuries
resulting from medicine injections. The anaerobic conditions in these settings
encourage the germination of C. botulinum spores and the toxin's generation,
which can cause a localized infection and possibly a systemic disease.

Incubation Period
 13

It's crucial to remember that, particularly in severe cases, botulism can

spread quickly once symptoms start to show. Effective therapy depends on early
detection and medical intervention. When botulism is suspected, one should
seek medical attention right away in order to receive the proper treatment, which
may include supportive care and the delivery of an antitoxin.

Susceptible Host
Animals: In some situations, a variety of animals may also be susceptible
to botulism. It is well known that birds, especially waterfowl like ducks and geese,
can become poisoned by botulism, which is typically caused by ingesting a toxin
found in rotting organic debris. Cattle and horses are examples of livestock that
can contract botulism; usually, this occurs when they consume tainted feed or
water.

In rare instances, humans may be exposed to botulism through the

consumption of tainted food, inhaled toxin, or wound contact with C. Spores of
botulinum. The most prevalent kind of botulism in people is called foodborne
botulism, which usually arises from eating food that has been incorrectly
prepared or kept and contains botulinum toxin.

Clinical Manifestations
Descending Paralysis: Botulism-related paralysis usually develops in a
descending manner, beginning with the muscles of the head and neck and
moving down to the limbs. Botulism is distinguished from other neuromuscular
illnesses by its distinct pattern of weakening and paralysis.

Autonomic Dysfunction: Botulism can also have an impact on

autonomic processes, resulting in symptoms like constipation, dry mouth, dry
eyes, urine retention, and decreased sweating. These symptoms arise from
botulinum toxin's suppression of acetylcholine release at autonomic nerve
terminals.

Diagnostic Examination
Isolation and Identification of Clostridium botulinum:
 Culture: Laboratory culture of clinical specimens, such as stool, wound
exudates, and food samples, may be performed to isolate Clostridium
botulinum. However, culturing C. botulinum can be challenging due to its
strict anaerobic requirements and the presence of competing bacteria in
clinical specimens.
 Toxin Detection: The primary method for diagnosing botulism is the
detection of botulinum toxin in clinical samples. Various methods can be
 14

used to detect the toxin, including enzyme-linked immunosorbent assay

(ELISA), mouse bioassay, and polymerase chain reaction (PCR) assays
targeting the genes encoding botulinum toxin.
 Identification: Once botulinum toxin is detected, further characterization
of the toxin type (e.g., types A, B, E) may be performed using specific
antibodies or molecular methods. This information can help guide
treatment decisions and public health interventions.

Management and Treatment

Supportive Care:
 Respiratory Support: Individuals with botulism may develop respiratory
muscle weakness or paralysis, leading to respiratory failure. Mechanical
ventilation may be required to support breathing until muscle function
improves. Close monitoring of respiratory function, including vital signs
and pulse oximetry, is essential.
 Nutritional Support: Individuals with severe botulism may have difficulty
swallowing (dysphagia) and may require enteral or parenteral nutrition to
meet their nutritional needs while maintaining airway protection.
 Hydration: Intravenous fluids may be administered to maintain hydration
and electrolyte balance, especially in individuals with prolonged illness or
gastrointestinal symptoms such as vomiting or diarrhea.

Prognosis
Complications: Aspiration pneumonia, respiratory failure, and secondary
infections are among the complications that can increase an affected person's
risk of morbidity and death from botulism. It is imperative to closely monitor and
manage difficulties in order to enhance outcomes and lower the likelihood of
long-term consequences.

Mild to Moderate Cases: With the right care, patients with mild to
moderate cases of botulism—which are characterized by localized muscle
paralysis and largely intact respiratory function—usually have a fair prognosis.
Over the course of a few days or weeks, these people may gradually see an
improvement in their symptoms, including a resolution of their muscle weakness
and a return to normal function.

Infection Prevention and Control Measures

Food Safety Practices:
 15

 Proper Canning and Food Preservation: Follow recommended

guidelines for canning, preserving, and storing food to prevent
contamination with C. botulinum spores. Use appropriate canning methods,
such as pressure canning for low-acid foods, to destroy botulinum spores.
 Avoidance of Home Canning of Certain Foods: Certain foods, such as
garlic in oil, are particularly conducive to the growth of C. botulinum and
should not be preserved at home unless using proper acidification or
refrigeration methods.
 Safe Handling of Commercially Canned Foods: Inspect canned foods
for signs of spoilage, such as bulging or leaking containers, before
consumption. Avoid consuming canned foods that appear damaged or
have an unusual odor.

Safe Infant Feeding Practices:

 Avoidance of Honey: Do not feed honey to infants under 12 months of
age, as it may contain C. botulinum spores that can cause infant botulism.
 Safe Handling of Baby Food: Ensure proper hygiene and sanitation when
preparing and handling baby food to prevent contamination with C.
botulinum spores.

Health Education
Follow-Up Care:
 Encourage patients to follow up with healthcare providers regularly,
especially if they have experienced botulism or are at increased risk of
infection.
 Provide resources for additional information and support, such as
community health services or support groups for individuals affected by
botulism.

 Recognition of Symptoms: Teach people to recognize the symptoms of

botulism, such as muscle weakness, double vision, difficulty speaking or
swallowing, and respiratory distress, and to seek medical attention
immediately if they experience these symptoms.

 Awareness of Rare Transmission Routes: While rare, individuals should be

aware of the potential for botulism transmission through inhalation in
certain settings and take appropriate precautions if working in laboratories
or other environments where aerosolized botulinum toxin may be a
concern.
 16

Diseases
Chlamydia

Pathogen
Chlamydia trachomatis, commonly known as chlamydia, is a bacterium
that causes chlamydia, which can manifest in various ways,
including: trachoma, lymphogranuloma venereum, nongonococcal
urethritis, cervicitis, salpingitis, pelvic inflammatory disease. C. trachomatis is the
most common infectious cause of blindness and the most common sexually
transmitted bacterium.

Chlamydia comprise a diverse group of obligate intracellular organisms

capable of causing respiratory disease in humans. Chlamydial infections are
frequently subclinical and of long duration. Epidemiology and presentation vary
from species to species. Chlamydia pneumonia causes a variety of respiratory
disease including pneumonia and bronchitis in adults and children and is
transmitted person to person. Clinically, pneumonia due to C. pneumonia cannot
be readily distinguished from community-acquired pneumonia caused by other
organisms, especially Mycoplasma pneumonia. Chlamydia trachomatis is
primarily a sexually transmitted infection, which can cause a distinctive
pneumonia in infants born to women with active genital infection. Chlamydia
psittaci is the causative agent of psittacosis, which is usually acquired from
exposure to sick birds.

Large amounts of unusual vaginal discharge. Frequent, painful urination.

Pain during sex. Bleeding between menstrual periods. Vaginal bleeding after sex,
not associated with a menstrual period
 17

Portal of Exit
Chlamydia spreads through vaginal, anal, or oral sex with someone with
the infection. Semen does not have to be present to get or spread the infection.
Pregnant people can give chlamydia to their baby during childbirth. This can
cause ophthalmia neonatorum (conjunctivitis) or pneumonia in some Also, you
can still get chlamydia even if your sex partner does not ejaculate (cum).
A pregnant person with chlamydia can give the infection to their baby during
childbirth.

Mode of Transmission
The Chlamydia trachomatis bacterium is most commonly spread through
vaginal, oral and anal sex. It also is possible for the bacterium to spread in
pregnancy, during delivery of the baby. Chlamydia can cause pneumonia or a
serious eye infection in the newborn. Pregnant people can give chlamydia to their
baby during childbirth. This can cause ophthalmia neonatorum (conjunctivitis) or
pneumonia in some infants. Rectal or genital infection can persist one year or
longer in infants infected at birth. However, sexual abuse should be a
consideration among young children with vaginal, urethral, or rectal infection
beyond the neonatal period. People treated for chlamydia can get the infection
again if they have sex with a person with chlamydia.

Portal of Entry
Chlamydia is a bacterial infection. The bacteria are usually spread
through sex or contact with infected genital fluids (semen or vaginal fluid). You
can get chlamydia through: unprotected vaginal, anal or oral sex. The urethra is
the most common site of infection in males, and the urethra and cervix are most
commonly infected in females.

Incubation Period
If you do get symptoms, these usually appear between 1 and 3 weeks
after having unprotected sex with an infected person. For some people they don't
develop until many months later. Sometimes the symptoms can disappear after a
few days. Chlamydia can cause serious problems if left untreated, particularly
among women. Women may develop pelvic inflammatory disease (PID), can
experience abdominal and pelvic pain, and in later stages develop infertility and
ectopic pregnancy (a pregnancy that occurs outside the womb). If given medicine
to take for seven days, wait until you finish all the doses before having sex. If
you've had chlamydia and took medicine in the past, you can still get it again.
This can happen if you have sex without a condom with a person who has
chlamydia.
 18

Susceptible Host
Sexually active young people are at a higher risk of getting chlamydia.
This is due to behaviors and biological factors common among young people.
Gay and bisexual men are also at risk since chlamydia can spread through oral
and anal sex seek testing. Chlamydia is most common among young people.
Two-thirds of new chlamydial infections occur among youth aged 15-24 years.
Estimates show that 1 in 20 sexually active young women aged 14-24 years has
chlamydia.

Clinical Manifestations
Many people with chlamydia have no symptoms or only mild symptoms. If
symptoms occur, they may not appear until up to three weeks after having sex
with someone who has chlamydia.

 In women, common symptoms include a change in vaginal

discharge,bleeding between menstrual periods or after sex, pain or
discomfort in the lower abdomen, burning sensation when urinating.
 Common symptoms in men include burning when urinating,discharge from
the penis,pain or discomfort in the testicles.
 Anal infection in women and men can causepain, discharge, bleeding.
Chlamydia can also infect the throat often without symptoms. Infants born
to mothers with chlamydia may experience eye infections or pneumonia.
These can be treated with antibiotic medications for newborns.

Chlamydia is a common STD that can cause infection among both men and
women. It can cause permanent damage to a woman's reproductive system. This
can make it difficult or impossible to get pregnant later. Chlamydia can also
cause a potentially fatal ectopic pregnancy (pregnancy that occurs outside the
womb). Chlamydia can usually be effectively treated with antibiotics. More than
95% of people will be cured if they take their antibiotics correctly. In
women, untreated chlamydia can cause pelvic inflammatory disease (PID),
ectopic pregnancy and infertility. In men, in rare cases, chlamydia can spread to
the testicles and epididymis (tubes that carry sperm from the testicles), causing
them to become painful and swollen.

Diagnostic Examination
Therefore, NAATs are generally considered the test of choice for
chlamydia and have replaced culture as the diagnostic gold standard. Antigen
tests (EIA, DFA, RDTs) are no longer recommended for chlamydia testing due to
insufficient diagnostic accuracy. The most commonly used type of chlamydia test
 19

is called a Nucleic Acid Amplification Test (NAAT). A NAAT detects the DNA of
the bacteria that cause the chlamydia infection NAATs are the most sensitive
tests to use on easy-to-obtain specimens. This includes vaginal swabs (either
clinician- or patient-collected) or urine sons destined for chlamydia screening.
Diagnostic procedures to detect CT infections include both direct and indirect
methods. Generally, localized infections were examined by assays for direct
pathogen detection, like culture, antigen tests (EIA, direct fluorescent antibody
(DFA), and immune chromatographic RDTs), nucleic acid hybridization and
amplification tests. Indirect methods depend on detection of antibodies against C.
trachomatis that may be applied for diagnostic evaluation of chronic/invasive
infection (PID, LGV) and post infectious complications, like sexually acquired
reactive arthritis (SARA). In these conditions, pathogens have crossed the
epithelial and may no longer be detectable in swabs. On the other hand, serology
is inappropriate to diagnose acute infections of the lower genital and anal tract,
as the antibody response becomes detectable only after weeks to months and is
often less pronounced.

Management and Treatment

Chlamydia can usually be effectively treated with antibiotics. More than
95% of people will be cured if they take their antibiotics correctly. You may be
started on antibiotics once test results have confirmed you have chlamydia.
Chlamydia can usually be effectively treated with antibiotics. More than 95% of
people will be cured if they take their antibiotics correctly. You may be started on
antibiotics once test results have confirmed you have chlamydia treatment for
uncomplicated urogenital chlamydia infection is with azithromycin. Doxycycline is
an alternative, but azithromycin is preferred as it is a single-dose therapy. Other
alternatives include erythromycin, levofloxacin, and ofloxacin.

You may be started on antibiotics once test results have confirmed you
have chlamydia. But if it's very likely you have the infection, you might be started
on treatment before you get your results. If you test positive for chlamydia, it's
important that your current sexual partner and any other recent sexual partners
you've had are also tested and treated. A specialist sexual health adviser can
help you contact your recent sexual partners, or the clinic can contact them for
you if you prefer. Either you or someone from the clinic can speak to them, or the
clinic can send them a note to let them know they may have been exposed to
a sexually transmitted infection (STI).

Prognosis
It is easily treated and cured with antibiotics. If not treated, chlamydia can
cause serious problems, including infertility and ectopic pregnancy. In pregnant
women, it can cause the baby to be born early (prematurity). Correct and
 20

consistent use of condoms during sex is the most effective way to prevent
chlamydia. Untreated STIs can lead to severe, lifelong health disorders, including
infertility, scarring, chronic pain, sexual dysfunction, HIV, and cancer. Chlamydia
is a common STD that can cause infection among both men and women. It can
cause permanent damage to a woman's reproductive system. This can make it
difficult or impossible to get pregnant later. Chlamydia can also cause a
potentially fatal ectopic pregnancy (pregnancy that occurs outside the womb.

Infection Prevention and Control Measures

Use a condom every time you have anal, vaginal, or oral sex. If you have
latex allergies, synthetic non-latex condoms can be used. But it is important to
note that these condoms have higher breakage rates than latex condoms.
Natural membrane condoms are not recommended for STD prevention.
Condoms, when used correctly, every time someone has sex can reduce the risk
of getting or giving chlamydia. The only way to completely avoid chlamydia is to
not have vaginal, anal, and oral sex. Latex condoms, when used consistently and
correctly, reduce the risk of transmission of STDs such as gonorrhea, chlamydia,
and trichomoniasis. STDs such as gonorrhea, chlamydia, and trichomoniasis are
sexually transmitted by genital secretions, such as urethral or vaginal secretions.
The surest way to prevent chlamydia is not to have sex or to have sex only with
someone who's not infected and who has sex only with you. Condoms can
reduce your risk of getting chlamydia if used the right way every single time you
have sex. Discuss testing for sexually transmitted infections with your doctor or
nurse. Ask if you are due for chlamydia screening. See your doctor or nurse if
you have any symptoms of chlamydia or another infection.

Health Education
The most effective way to prevent chlamydia is to avoid sexual intercourse.
Because this is not practical for most people, the following tips are
recommended: Use condoms every time you have sex. Discuss testing for
sexually transmitted infections with your doctor or nurse. As a nurse, i will
educate my patient by discussing on how to prevent chlamydia infections by
encourage patient to practice safe sex, Encourage the use of condoms,
Encourage patient to remain compliant with medications, Check labs for culture
result, administer antibiotics as ordered, check labs to ensure female is not
pregnant as doxycycline cannot be given in pregnancy, encourage the patient to
notify the partner to come in for a screening test, encourage patient to follow up
in the STD clinic.
 21

Diseases
Gonorrhea

Pathogen
Neisseria gonorrhea is a bacterial pathogen responsible for gonorrhea and
various sequelae that tend to occur when asymptomatic infection ascends within
the genital tract or disseminates to distal tissues. Global rates of gonorrhea
continue to rise, facilitated by the emergence of broad-spectrum antibiotic
resistance that has recently afforded the bacteria ‘superbug’ status. N. gonorrhea
is exquisitely adapted to life in humans, having evolved novel strategies to
succeed in their restricted mucosal niche. Gonococci also represent a paradigm
for bacterial immune evasion due to its genetically plastic lifestyle and ability to
directly suppress otherwise protective adaptive responses, allowing the bacteria
to persist within an infected individual and re-infect individuals who have had
prior infection.

The causative agent of gonorrhea is the bacterium Neisseria gonorrhea,

also known as gonococcus. This bacterium is a gram-negative diplococcus,
meaning it appears under a microscope as pairs of spherical cells. Neisseria
gonorrhea exclusively infects humans and primarily targets the mucous
membranes of the reproductive tract (urethra in males and cervix in females),
rectum, throat, and occasionally other mucosal surfaces.

Portal of Exit
 22

Gonorrhea is a sexually transmitted infection caused by the bacterium

Neisseria gonorrhea. The portal of exit for gonorrhea in infected individuals
depends on the site of infection:

Genital Infections:
 For males with urethral gonorrhea (urethritis), the portal of exit is through
the urethra during ejaculation.
 For females with cervical gonorrhea, the bacteria can exit through the
cervix.
Rectal Infections:
 In cases of rectal gonorrhea, the portal of exit is typically through the anus
during bowel movements.
Pharyngeal Infections:
 Gonorrhea can also infect the throat (pharynx) through oral sex, and the
portal of exit here would be through saliva or mucous membranes in the
throat.

Mode of Transmission
Gonorrhea can be transmitted from one individual to another through
various forms of sexual contact, including vaginal, anal, or oral sex. During these
activities, the bacteria Neisseria gonorrhea can be passed from an infected
person to their partner through contact with infected genital secretions, such as
semen or vaginal fluids, sexual contact with the penis, vagina, mouth, or anus of
an infected partner. Mainly doesn’t cause symptoms, this makes it easy to infect
your partners unknowingly. Additionally, gonorrhea can also be transmitted from
an infected mother to her baby during childbirth.

Portal of Entry
The primary portal of entry for gonorrhea is the mucous membranes of the
genital tract during sexual activity. This includes the urethra in males and the
cervix in females. Gonorrhea can also infect other mucous membranes such as
those in the rectum and throat if there is contact with infected bodily fluids during
anal or oral sex, respectively. Once the Neisseria gonorrhea bacteria gain access
to these mucosal surfaces, they can adhere and penetrate epithelial cells,
leading to infection.

Incubation Period
The incubation period of gonorrhea typically ranges from 2 to 14 days
after exposure to the Neisseria gonorrhea bacteria. However, it's important to
note that the incubation period can vary from person to person. Some individuals
may develop symptoms sooner, while others may remain asymptomatic for a
longer period. It's also possible for symptoms to appear weeks or even months
 23

after exposure. N. gonorrhea is a fastidious organism that is sensitive to many

environmental factors such as oxygen, non-physiological temperatures,
desiccation and the presence of toxic substances (such as many fatty acids),
among others; thus, the bacterium does not survive for long outside the human
host, and is difficult to culture. Many strains have incomplete biosynthetic
capabilities for amino acids, presumably because amino acids and other
important nutrients are readily obtained from the human host. Iron (which is
essential for bacterial growth) is acquired from the host by binding iron-containing
host proteins such as transferrin, lactoferrin and hemoglobin at the bacterial
surface and stripping these molecules of iron that is then delivered to the
bacterial cytoplasm. Owing to the broad range of oxygen levels within different
niches of the male and female urogenital tracts, it is possible that N. gonorrhea
encounters aerobic, microaerobic, and anaerobic conditions within the host, and
the bacteria are able to grow in all these conditions.

Susceptible Host
A susceptible host for gonorrhea is any individual who comes into contact
with the Neisseria gonorrhea bacteria and lacks immunity or has not been
previously infected. This includes individuals who engage in unprotected sexual
activity with an infected partner. Susceptibility can vary based on factors such as
age, gender, sexual practices, and overall health status. Additionally, certain
populations, such as sexually active adolescents and young adults, may be at
higher risk of contracting gonorrhea due to behavioral and biological factors.

 Sexually active individuals: Gonorrhea is primarily transmitted through

sexual contact, including vaginal, anal, and oral sex. Therefore, individuals
who are sexually active and engage in unprotected sex are at higher risk
of contracting gonorrhea.
 Young adults: Young adults, particularly those aged 15 to 24, have been
identified as a high-risk group for gonorrhea. This may be due to factors
such as increased sexual activity, multiple partners, and inconsistent
condom use.
 People with multiple sexual partners: Having multiple sexual partners
or having a partner who has multiple partners increases the risk of
exposure to gonorrhea and other sexually transmitted infections (STIs).
 People with a history of STIs: Individuals who have had gonorrhea or
other STIs in the past are at higher risk of contracting gonorrhea again if
they engage in unprotected sex.
 Individuals with compromised immune systems: Conditions or
medications that weaken the immune system can increase susceptibility to
gonorrhea and other infections. This includes conditions such as
HIV/AIDS and certain autoimmune disorders, as well as medications such
as corticosteroids and chemotherapy drugs.
 24

 Certain behavioral factors: Engaging in high-risk sexual behaviors, such

as unprotected sex with anonymous partners or exchanging sex for
money or drugs, can increase the likelihood of gonorrhea transmission.

Clinical Manifestations
Gonorrhea can manifest with a variety of signs and symptoms, some of
which are unique to the disease. The cardinal signs specific to gonorrhea
include:

1. Urethral Discharge: In males, a thick, pus-like discharge from the penis is a

hallmark symptom. The discharge may be yellowish, greenish, or white in
color and is often accompanied by a burning sensation during urination.
2. Vaginal Discharge: In females, gonorrhea can cause an increase in vaginal
discharge that may be yellowish or bloody. The discharge may have a strong
odor and may be accompanied by pain or burning during urination.
3. Rectal Symptoms: Anal intercourse can lead to rectal infection with
gonorrhea, resulting in symptoms such as anal itching, soreness, discharge,
and painful bowel movements.

4. Pharyngeal Symptoms: Gonorrhea can infect the throat through oral sex,
causing symptoms such as sore throat, difficulty swallowing, and swollen
lymph nodes in the neck.

Other signs and symptoms of gonorrhea, which may not be unique to the
disease, include:
 Painful or swollen testicles in males (epididymitis)
 Lower abdominal or pelvic pain in females
 Painful intercourse
 Abnormal menstrual bleeding
 Conjunctivitis (if infected fluids come into contact with the eyes)
 Asymptomatic infection (many individuals, particularly females, may not
exhibit any symptoms)

Diagnostic Examination
Diagnostic examination for gonorrhea typically involves laboratory testing to
detect the presence of the Neisseria gonorrhea bacteria. Common diagnostic
methods include:

 Nucleic Acid Amplification Tests (NAATs): These tests are highly

sensitive and specific and are the preferred method for diagnosing
gonorrhea. NAATs detect the genetic material (DNA or RNA) of the
bacteria in urine samples, genital swabs, or other clinical specimens.
 25

 Gram Stain: A gram stain of urethral, vaginal, or cervical discharge can

reveal the presence of gram-negative diplococci, which are characteristic
of Neisseria gonorrhea. However, gram stain has lower sensitivity
compared to NAATs and may miss asymptomatic infections.
 Culture: Culturing the bacteria from clinical specimens can also be used
for diagnosis. However, culture methods are less commonly used due to
their lower sensitivity and longer turnaround time compared to NAATs.
 Point-of-care Tests (POCT): Rapid diagnostic tests (such as nucleic acid
amplification-based or antigen-based tests) are available for use in some
settings, providing quick results within minutes to hours.

Management and Treatment

The management and treatment of gonorrhea typically involve antibiotic
therapy to clear the infection and prevent complications. Here are the general
steps and considerations for managing and treating gonorrhea:

 Diagnosis: Gonorrhea is diagnosed through laboratory testing of samples

collected from the site of infection (e.g., urine, swabs from genital, rectal,
or pharyngeal sites). Diagnosis may also involve testing for other sexually
transmitted infections (STIs) due to possible co-infection.

 Treatment Guidelines: Treatment guidelines for gonorrhea may vary

based on regional antimicrobial resistance patterns. The Centers for
Disease Control and Prevention (CDC) and other health authorities
regularly update guidelines based on current resistance data. Commonly
recommended treatments include dual therapy with two antibiotics to
ensure effective treatment and reduce the risk of developing antibiotic
resistance.

 Antibiotic Therapy:
The recommended first-line treatment for uncomplicated gonorrhea often
involves a single intramuscular injection of ceftriaxone (a third-generation
cephalosporin) combined with an oral dose of azithromycin (to cover
potential concurrent chlamydial infection).
Alternative treatments might be considered based on local resistance
patterns and individual patient factors (e.g., allergies)

 Partner Notification and Treatment: Sexual partners of individuals

diagnosed with gonorrhea should be notified and encouraged to seek
testing and treatment to prevent reinfection and further transmission.
 26

 Follow-Up Testing: Patients treated for gonorrhea should undergo follow-

up testing to ensure that the infection has been successfully cleared. This
follow-up is crucial due to rising antibiotic resistance in Neisseria
gonorrhea.

 Prevention Counseling: Counseling on safe sex practices, including

consistent and correct use of condoms, can help prevent future infections
and the spread of gonorrhea and other STIs.

Complications and Additional Management:

 Complications of untreated gonorrhea can include pelvic inflammatory
disease (PID) in women, epididymitis in men, and increased risk of HIV
transmission.
 Patients with complications or treatment failures may require additional
evaluation, prolonged therapy, or referral to specialists for further
management.

It's important for individuals diagnosed with gonorrhea to complete the full
course of treatment as prescribed by their healthcare provider, even if symptoms
improve. Additionally, practicing safe sex and seeking regular STI screenings are
essential for preventing and controlling gonorrhea and other sexually transmitted
infections. If you suspect you have gonorrhea or have been exposed to it,
promptly consult a healthcare professional for diagnosis and appropriate
treatment.

Prognosis
The prognosis of individuals who have contracted gonorrhea is generally
good with prompt diagnosis and appropriate treatment. According to the Centers
for Disease Control and Prevention (CDC), uncomplicated gonorrhea infections
can be effectively treated with antibiotics. However, untreated or inadequately
treated gonorrhea can lead to serious complications such as pelvic inflammatory
disease (PID), infertility, ectopic pregnancy, chronic pelvic pain, and an increased
risk of HIV transmission. Additionally, gonorrhea infection during pregnancy can
result in adverse outcomes for both the mother and the baby. It's essential for
individuals diagnosed with gonorrhea to complete the full course of antibiotics as
prescribed by their healthcare provider and to follow up for retesting as
recommended to ensure the infection has been fully treated. Early detection and
treatment of gonorrhea are critical to preventing complications and reducing the
risk of transmission to others. Adults with gonorrhea are treated with antibiotics.
Due to emerging strains of drug-resistant Neisseria gonorrhea, the bacterium that
causes gonorrhea, the Centers for Disease Control and Prevention recommends
that uncomplicated gonorrhea be treated with the antibiotic ceftriaxone. This
antibiotic is given as a shot, also called an injection. After getting the antibiotic,
 27

you can still spread the infection to others for up to seven days. So avoid sexual
activity for at least seven days. Three months after treatment, the CDC also
recommends getting tested for gonorrhea again. This is to make sure people
haven't been reinfected with the bacteria, which can happen if sex partners aren't
treated, or new sex partners have the bacteria.

Infection Prevention and Control Measures

Preventing or controlling the spread of gonorrhea involves a combination of
individual behavior changes, public health interventions, and healthcare
strategies. Here are some key measures:

 Safe Sexual Practices: Using condoms consistently and correctly during

vaginal, anal, and oral sex can significantly reduce the risk of gonorrhea
transmission. Limiting the number of sexual partners and choosing
partners who have been tested for sexually transmitted infections (STIs)
can also lower the risk.
 Regular Testing: Individuals who are sexually active, especially those
with multiple partners or who engage in high-risk behaviors, should
undergo regular STI testing, including testing for gonorrhea. Early
detection allows for prompt treatment and reduces the risk of
complications and further transmission.
 Treatment of Infected Individuals: Prompt diagnosis and treatment of
gonorrhea-infected individuals are crucial to prevent the spread of the
infection. Healthcare providers should prescribe appropriate antibiotics
and ensure that patients complete the full course of treatment as directed.
 Partner Notification and Treatment: Infected individuals should inform
their sexual partners about their diagnosis so that they can also seek
testing and treatment. Partner notification programs, facilitated by
healthcare providers or public health agencies, can help identify and treat
additional cases of gonorrhea.
 Health Education and Awareness: Public health campaigns and
educational initiatives can raise awareness about gonorrhea, its
transmission, prevention methods, and the importance of testing and
treatment. These efforts aim to promote healthy sexual behaviors and
reduce stigma associated with STIs.
 Screening and Treatment Programs: Healthcare providers and public
health agencies may implement screening programs targeting populations
at higher risk of gonorrhea, such as sexually active adolescents, young
adults, men who have sex with men (MSM), and individuals living in areas
with high STI prevalence. Accessible and affordable testing and treatment
services are essential components of these programs.
 Antibiotic Resistance Surveillance: Monitoring antibiotic resistance
patterns of Neisseria gonorrhea is critical to guide treatment
 28

recommendations and identify emerging resistant strains. Healthcare

providers should follow treatment guidelines that consider local resistance
patterns and prescribe appropriate antibiotics.

Health Education
As a nurse, educating patients about gonorrhea prevention, signs and
symptoms, and possible complications is essential for promoting sexual health.
Here's a comprehensive guide on how to educate patients:

Prevention of Gonorrhea:
 Emphasize the importance of practicing safe sex by using condoms
consistently and correctly during vaginal, anal, and oral sex to reduce
the risk of gonorrhea transmission.
 Encourage limiting the number of sexual partners and choosing
partners who have been tested for sexually transmitted infections
(STIs).
 Discuss the benefits of regular STI testing, especially for individuals
with multiple sexual partners or who engage in high-risk behaviors.
 Highlight the role of open communication with sexual partners about
STI testing and prevention strategies.

Diet and Lifestyle Recommendations:

 While diet doesn't directly prevent gonorrhea, maintaining overall good

health can support the immune system's ability to fight infections.
Encourage patients to consume a balanced diet rich in fruits, vegetables,
whole grains, lean proteins, and healthy fats.
 Stress the importance of staying hydrated and getting regular exercise to
support overall well-being and immune function.

Signs and Symptoms of Gonorrhea:

Educate patients about the common signs and symptoms of gonorrhea, which
may include:
 Genital discharge (yellowish, greenish, or white) in males and females
 Pain or burning during urination
 Rectal symptoms (itching, soreness, discharge) if infection occurs in the
rectum
 Pharyngeal symptoms (sore throat, difficulty swallowing) if infection occurs
in the throat
 Emphasize that gonorrhea can also be asymptomatic, especially in
females, so regular testing is important, regardless of symptoms.
 29

Discuss potential complications of untreated or inadequately treated gonorrhea,

including:
 Pelvic inflammatory disease (PID) in females, which can lead to infertility,
chronic pelvic pain, and ectopic pregnancy.
 Epididymitis (inflammation of the epididymis) in males, which can lead to
infertility if left untreated.
 Disseminated gonococcal infection (DGI), a rare but serious complication
that can affect multiple organs and cause joint pain, skin rash, and fever.
 Increased risk of HIV transmission.
 Stress the importance of seeking medical care promptly if symptoms
develop and completing the full course of antibiotics as prescribed by a
healthcare provider.

Follow-Up and Additional Resources:

 Provide information on where patients can access STI testing and
treatment services in their community.
 Encourage patients to follow up for retesting as recommended by their
healthcare provider, especially if they have been diagnosed with
gonorrhea or have had sexual contact with an infected partner.
 Offer educational materials or online resources for further information on
sexual health and gonorrhea prevention.
 By providing comprehensive education on gonorrhea prevention, signs
and symptoms, and potential complications, nurses can empower patients
to make informed decisions about their sexual health and reduce the risk
of gonorrhea transmission and associated complications.

Diseases
Legionellosis

Pathogen
According to the World Health Organization (September 22) causative
agents of Legionella bacteria came from water or potting mix. The most common
cause of illness is the freshwater species L. pneumophila, which is found in
natural aquatic environments worldwide. However, artificial water systems which
 30

provide environments conducive to the growth and dissemination

of Legionella represent the most likely sources of disease.
The bacteria live and grow in water systems at temperatures of 20 to 50
degrees Celsius (optimal 35 degrees Celsius). Legionella can survive and grow
as parasites within free-living protozoa and within biofilms which develop in water
systems. They can cause infections by infecting human cells using a similar
mechanism to that used to infect protozoa.

Portal of Exit

Mode of Transmission
The most common form of transmission of Legionella is inhalation of
contaminated aerosols from contaminated water. Sources of aerosols that have
been linked with transmission of Legionella include air conditioning cooling
towers, hot and cold-water systems, humidifiers, and whirlpool spas. Infection
can also occur by aspiration of contaminated water or ice, particularly in
susceptible hospital patients, and by exposure of babies during water births. To
date, there has been no reported direct human-to-human transmission.

Portal of Entry
After Legionella grows and multiplies in a building water system, water
containing Legionella can spread in droplets small enough for people to breathe
in. People can get Legionnaires’ disease or Pontiac fever when they breathe in
small droplets of water in the air that contain the bacteria.
Less commonly, people can get sick by aspiration of drinking water
containing Legionella. This happens when water accidently goes into the lungs
while drinking. People at increased risk of aspiration include those with
swallowing difficulties.
In general, people do not spread Legionnaires’ disease and Pontiac fever
to other people. However, this may be possible under rare circumstances.

Incubation Period
Legionellosis is a generic term describing the pneumonic and non-
pneumonic forms of infection with Legionella.

The non-pneumonic form (Pontiac disease) is an acute, self-limiting

influenza-like illness usually lasting 2–5 days. The incubation period is from a few
and up to 48 hours. The main symptoms are fever, chills, headache, malaise,
and muscle pain (myalgia). No deaths are associated with this type of infection.
Legionnaires’ disease, the pneumonic form, has an incubation period of 2
to 10 days (but up to 16 days has been recorded in some outbreaks). Initially,
symptoms are fever, loss of appetite, headache, malaise, and lethargy. Some
patients may also have muscle pain, diarrhoea and confusion. There is also
 31

usually an initial mild cough, but as many as 50% of patients can present
phlegm. Blood-streaked phlegm or hemoptysis occurs in about one-third of the
patients. The severity of disease ranges from a mild cough to a rapidly fatal
pneumonia. Death occurs through progressive pneumonia with respiratory failure
and/or shock and multi-organ failure.
Untreated Legionnaires’ disease usually worsens during the first week. In
common with other risk factors causing severe pneumonia, the most frequent
complications of legionellosis are respiratory failure, shock and acute kidney and
multi-organ failure. Recovery always requires antibiotic treatment, and is usually
complete, after several weeks or months. In rare occasions, severe progressive
pneumonia or ineffective treatment for pneumonia can result in brain sequelae.
The death rate as a result of Legionnaires’ disease depends on the
severity of the disease, the appropriateness of initial anti-microbial treatment, the
setting where Legionella was acquired, and host factors (for example, the
disease is usually more serious in patients with immuno-suppression). The death
rate may be as high as 40–80% in untreated immuno-suppressed patients and
can be reduced to 5–30% through appropriate case management and depending
on the severity of the clinical signs and symptoms. Overall, the death rate is
usually within the range of 5–10%.

Susceptible Host
The most susceptible hosts are immuno-compromised patients, including
organ transplant recipients and cancer patients and those receiving corticosteroid
treatment.
Delay in diagnosis and administration of appropriate antibiotic treatment,
increasing age and presence of co-existing diseases are predictors of death from
Legionnaires’ disease.

Clinical Manifestations

Clinical Manifestations Legionnaires’ disease is very similar to other types of

pneumonia (lung infection), with symptoms that include:
 Fever (often over 104⁰F/40⁰C).
 Cough (usually dry).
 Shortness of breath (dyspnea).
 Diarrhea.
 Muscle aches.
 Headache.
 Nausea.
 Confusion.
 Coughing up blood (hemoptysis).
 Stomach (abdominal) pain.
 32

Legionnaires’ disease can also be associated with other symptoms such as

diarrhea, nausea, and confusion. Symptoms usually begin 2 to 14 days after
being exposed to the bacteria, but it can take longer.

Diagnostic Examination
The preferred diagnostic tests for Legionnaires’ disease are culture of
lower respiratory secretions (e.g., sputum, bronchoalveolar lavage) on selective
media and the Legionella urinary antigen test.
1. Culture
Isolation of Legionella on media that supports growth of Legionella (i.e.,
Buffered Charcoal Yeast Extract [BCYE] agar) is confirmatory and an important
method for diagnosis. Isolation of Legionella can come from lower respiratory
secretions, lung tissue, pleural fluid, or a normally sterile site. Culturing
specimens can detect Legionella species and serogroups that the urinary antigen
test does not.
2. Urinary Antigen Test
The most used laboratory test for diagnosis of Legionnaires’ disease is the
urinary antigen test (UAT), which detects a molecule of the Legionella bacterium
in urine. If the patient has pneumonia and the test is positive, then you should
consider the patient to have Legionnaires’ disease. The test can remain positive
for a few weeks after infection, even with antibiotic treatment. The UAT detects
the most common cause of Legionnaires’ disease, L. pneumophila serogroup 1.

3. Use Culture and Urinary Antigen Tests in Combination

Unlike the urinary antigen test, culturing specimens from patients can detect
all species and serogroups of Legionella Isolating Legionella from clinical
specimens helps investigators identify where exposure occurred and prevent
additional cases.
4. Other tests might include:
Blood and urine tests Chest X-ray, which doesn't confirm Legionnaires'
disease but can show the extent of infection in your lungs an tests on a sample
of your sputum or lung tissue

Management and Treatment

1. Inpatient care
 Most patients with Legionnaires disease (LD) require initial
hospitalization for intravenous antibiotics.
 Closely monitor patients for signs of shock and/or respiratory or
multiorgan failure and the need for ICU care.
 Patients who begin to steadily improve can be switched to oral
antibiotics. Continue to monitor patients in the hospital for at least 1
 33

day after switching to oral antimicrobial therapy because relapse is

possible.
2. Surgical care
 Surgical drainage of pulmonary or extrapulmonary disease may be
necessary.
3. Outpatient care
 Outpatient treatment with oral antibiotics may be considered for
selected patients with mild disease if they can be closely monitored
for signs of deterioration.
 Continue outpatient treatment after the patient is discharged from
the hospital until antibiotic therapy is completed and symptoms
resolve.
4. Medical Care
 Legionnaires disease (LD), a high level of suspicion and prompt
initiation of adequate antimicrobial therapy are critical to improve
clinical outcomes.
Prognosis
Possible complications of Legionnaires’ disease include Lung failure and
Death About 1 out of every 10 people who gets sick with Legionnaires’ disease
will die due to complications from their illness.1 For those who get Legionnaires’
disease during a stay in a healthcare facility

Infection Prevention and Control Measures

Treatments exist, but there is no vaccine currently available for
Legionnaires’ disease.
The nonpneumonic form of infection is self-limiting and does not require
medical interventions, including antibiotic treatment. Patients with Legionnaires’
disease always require antibiotic treatment following diagnosis.
The public health threat posed by legionellosis can be addressed by
implementing water safety plans by authorities responsible for building safety or
water system safety. These plans must be specific to the building or water
system and should result in the introduction and regular monitoring of control
measures against identified risks including Legionella. Although it is not always
possible to eradicate the source of infection, it is possible to reduce the risks
substantially.
Prevention of Legionnaires’ disease depends on applying control
measures to minimize the growth of Legionella and dissemination of aerosols.
These measures include good maintenance of devices, including regular
cleaning and disinfection and applying other physical (temperature) or chemical
measures (biocide) to minimize growth. Some examples are:
 the regular maintenance, cleaning and disinfection of cooling
towers together with frequent or continuous addition of biocides.
 installation of drift eliminators to reduce dissemination of aerosols
from cooling towers; maintaining an adequate level of a biocide
 34

such as chlorine in a spa pool along with a complete drain and

clean of the whole system at least weekly.
 keeping hot and cold water systems clean and either keeping the
hot water above 50 °C (which requires water leaving the heating
unit to be at or above 60 °C) and the cold below 25 °C and ideally
below 20 °C or alternatively treating them with a suitable biocide to
limit growth, particularly in hospitals and other health care settings,
and aged-care facilities; and reducing stagnation by flushing
unused taps in buildings on a weekly basis.
Applying such controls will greatly reduce the risk of Legionella
contamination and prevent the occurrence of sporadic cases and outbreaks.
Extra precautions may be required for water and ice provided to highly
susceptible patients in hospitals including those at risk of aspiration (for example,
ice machines can be a source of Legionella and should not be used by highly
susceptible patients).

Health Education

Pathogen

•Caused by M.leprae and M. Lepromatosis bacteria.

• The exact route of transmission is not known, but it is likely to spread through
respiratory droplets of cough or sneezing of an infected person.
•Risk factors for developing leprosy include:
•Close contact with the infected person
•Reduced immune function
•Malnutrition
•Those living in poverty

Sources;Dr. Aakash Gupta

verified specialist
MBBS, MD, FRGUHS Der

Portal of Exit

Mycobacterium leprae, an acid-fast rod-shaped bacillus, is the cause of

leprosy. Unfortunately, because of its poor replication and lack of genes
necessary for independent existence, it has never been cultivated in bacteriologic
media Alternatively, lepromatous nodule ground tissue or nasal scrapings from
leprosy patients can be injected into mouse foot pads to grow it. The granuloma
usually develops at the injection site six months after the injection. Armadillos are
helpful for researching Hansen's disease and its treatment because they can also
 35

be experimentally infected and acquire systemic disease Leprosy's precise

manner and route of transmission are yet unknown, but the disease can be cured
with early detection and treatment.

Mode of Transmission

The exact route of transmission is not fully understood, but it is believed to

occur through respiratory droplets when an infected person coughs or sneezes.
Close and frequent contact with an untreated individual is typically required for
transmission.
It's crucial to remember that leprosy is not very communicable and that most
people naturally resist the infection. Additionally, incidental contact like
handshakes, hugs, or sitting next to someone on a bus cannot spread the
disease. Moreover, a person with leprosy rapidly ceases to be contagious after
starting therapy.

Leprosy is primarily transmitted through droplets from the nose and mouth of an
untreated person.
Prolonged, close contact over months with someone who has untreated leprosy
is necessary to contract the disease.
Casual contact (such as shaking hands, hugging, or sharing meals) does not
spread leprosy.
Patients stop transmitting the disease once they begin treatment.

Portal of Entry

may happen when a person with Hansen's disease coughs or sneezes,

and a healthy person breathes in the droplets containing the bacteria. Prolonged,
close contact with someone with untreated leprosy over many months is needed
to catch the disease.
Transmission occurs through inhalation of bacilli present in upper airway
secretion. The nasal mucosa is the main entry or exit route of M. leprae.

but household and prolonged close contact is important. The germs probably
enter the body through the nose and possibly through broken skin. The germs
get in the air through nasal discharge of untreated lepromatous patients.
Incubation Period

The incubation period for leprosy, caused by the bacterium

Mycobacterium leprae, is quite variable. On average, symptoms may appear
within five years after exposure. However, in some cases, it can take as long as
20 years for symptoms to develop. The usual incubation period ranges from 6
months to 10 years. Once infection develops, hematogenous dissemination can
occur.
 36

Susceptible Host

Leprosy is a chronic mycobacteriosis with high infectivity and low

pathogenicity. It is caused by Mycobacterium leprae, whose main host is humans

Clinical Manifestations

Symptoms mainly affect the skin, nerves, and mucous membranes (the
soft, moist areas just inside the body’s openings).

The disease can cause skin symptoms such as:

Discolored patches of skin, usually flat, that may be numb and look faded (lighter
than the skin around)
Growths (nodules) on the skin
Thick, stiff or dry skin
Painless ulcers on the soles of feet
Painless swelling or lumps on the face or earlobes
Loss of eyebrows or eyelashes
Symptoms caused by damage to the nerves are:

Numbness of affected areas of the skin

Muscle weakness or paralysis (especially in the hands and feet)
Enlarged nerves (especially those around the elbow and knee and in the sides of
the neck)
Eye problems that may lead to blindness (when facial nerves are affected)
Enlarged nerves below the skin and dark reddish skin patch overlying the nerves
affected by the bacteria on the chest of a patient with Hansen’s disease. This
skin patch was numb when touched.

Symptoms caused by the disease in the mucous membranes are:

 A stuffy nose
 Nosebleeds
 Since Hansen’s disease affects the nerves, loss of feeling or sensation can
occur. When loss of sensation occurs, injuries such as burns may go
unnoticed. Because you may not feel the pain that can warn you of harm to
your body, take extra caution to ensure the affected parts of your body are
not injured.

If left untreated, the signs of advanced leprosy can include:

 Paralysis and crippling of hands and feet

 Shortening of toes and fingers due to reabsorption
 Chronic non-healing ulcers on the bottoms of the feet
Blindness
 37

Loss of eyebrows
Nose disfigurement
Other complications that may sometimes occur are:

Painful or tender nerves

Redness and pain around the affected area
Burning sensation in the skin

Diagnostic Examination
This disease has a clinical diagnosis. To classify leprosy's clinical form or
confirm the diagnosis, laboratory testing is required in some circumstances.
Through a review of auxiliary laboratory techniques that can be used for leprosy
diagnosis—such as Mitsuda intradermal reaction, skin smear microscopy,
histopathology, serology, immunohistochemistry, polymerase chain reaction,
imaging tests, electromyography, and blood tests—this article seeks to inform
dermatologists about leprosy. It also tries to describe common multidrug therapy
regimens, chemoprophylaxis, immunotherapy with the bacillus Calmette-Guérin
(BCG) vaccination, and the management of reactions and resistant cases.
Treatment typically involves multi-drug therapy with antibiotics such as dapsone,
rifampicin, and clofazimine. Anti-inflammatory drugs like aspirin and prednisone
may be used to control nerve pain and damage. In some cases, neural or
reconstructive surgery may be necessary.

It’s important for healthcare providers to follow the latest guidelines and protocols
to ensure accurate diagnosis and effective treatment of leprosy.

Management and Treatment

The management and treatment of diseases can vary widely depending

on the specific condition, but generally, they can include a combination of lifestyle
changes, medication, therapy, and in some cases, surgical interventions.

Lifestyle Changes:
•Healthy diet: Nutrition plays a crucial role in managing many diseases.
•Exercise: Regular physical activity can help manage symptoms and improve
overall health.
•Stress management: Techniques like meditation can be beneficial.
Medication:
•Prescription drugs: These are often used to treat symptoms and manage
disease progression.
•Over-the-counter (OTC) medication: Can be used for symptom relief in some
diseases.
 38

Therapy:
•Physical therapy: Helps improve mobility and function.
•Occupational therapy: Assists in adapting to daily activities.
•Speech therapy: Used for conditions affecting speech.
Surgical Interventions:
•Curative surgery: Aims to remove the disease from the body.
•Palliative surgery: Helps relieve symptoms without curing the disease.
•Reconstructive surgery: Restores appearance or function following disease
treatment.
Alternative Treatments:
•Herbal remedies: Some conditions may benefit from natural products.
•Acupuncture: Can help manage pain and other symptoms.
Supportive Care:
•Counseling: To help cope with the emotional aspects of a disease.
•Support groups: Provide a community for sharing experiences and advice.
•Regular check-ups: To monitor the disease and adjust treatments as
necessary.
•Home monitoring: Such as blood pressure or blood sugar levels, depending on
the disease.
It’s important to consult healthcare professionals for a personalized treatment
plan
Prognosis
It is highly dependent on early detection and adherence to the treatment
regimen. Cure rates are high, but relapse may occur months or years after
treatment has been
stopped.

Infection Prevention and Control Measures

The best way to prevent catching leprosy is to avoid direct and prolonged contact
with untreated patients (especially for young children). Other ways to reduce the
risk of getting leprosy include practicing personal hygiene, and maintaining a
healthy lifestyle through eating healthy food, having enough rest and exercise,
and keeping a clean environment.
 39

If someone becomes a close contact of an individual with leprosy, that person

may be given an antibiotic called rifampicin, which has been shown to help
prevent the development of leprosy.

While the BCG vaccine (which is primarily used against tuberculosis) may offer
protection against leprosy, its efficacy is not consistent, making it not a cost-
effective preventive measure.

People living in the same household as the affected individual should be

examined for leprosy and treated if symptoms are present.
BCG vaccine offers some protection against leprosy.
Early diagnosis of the condition can help prevent spreading.

References;Dr. Aakash Gupta

verified specialist
MBBS, MD, FRGUHS Der

Health Education
As a nurse Educating patients about leprosy is crucial for both managing the
disease and preventing its spread.

Teach patients to recognize symptoms such as light-colored or red skin

patches, numbness, muscle weakness, and eye problems.
Inform patients that leprosy is likely spread through respiratory droplets but
requires prolonged close contact.

-Inform patients that leprosy is likely spread through respiratory droplets but
requires prolonged close contact. It’s not spread by casual contact like shaking
hands or sitting next to someone.
-Discuss the multi-drug therapy available for leprosy, which is highly effective if
started early. Treatment can prevent disability and stop the transmission of the
disease..
-Advise on a balanced diet rich in Vitamin A, zinc, and omega-3, which can
support skin health and the immune system1
-Encourage patients to share their knowledge about leprosy with their community
to reduce fear and misinformation.

Sources;https://www.who.int/news-room/fact-sheets/detail/leprosy

Do these parts for every Diseases

Conclusion

Leprosy is a major public health concern worldwide. All healthcare

workers must have basic knowledge of this disease to diagnose it, treat patients
in a timely manner, and prevent disability and/or disease spread. The
 40

development of improved diagnostic and therapeutic methods for leprosy

remains a significant challenge. This review provides some knowledge on the
epidemiology, clinical diagnosis, and management of leprosy and makes it
possible to eliminate leprosy worldwide. Further studies on the impact of leprosy
on stigma, discrimination, and mental health are required.

References

Botulism - Google Search. (n.d.). https://www.google.com/ search?

q=botulism&oq=b otulism&gs _lc rp = Eg
ZjaHJvbWUqDggAEEUYJxg7GIAEGIoFMg4IABBFGCcYOxiABBiKBTIKC
AEQABixAxiABDIHCAIQABiABDIHCAMQLhiABDIHCAQQABiABDIHCAU
QABiABDIHCAYQABiABDIGCAcQRRg9qAIAsAIA&sourceid=chrome&ie=
UTF-8

Botulism | Botulism | CDC. (n.d.-b). https://www.cdc.gov/botulism/index.html

Botulism - Symptoms and causes - Mayo Clinic. (2022, July 12). Mayo Clinic.
https://www.mayoclinic.org/diseases-conditions/botulism/symptoms-
causes/syc-20370262

Detels R, Green AM, Klausner JD, Katzenstein D, Gaydos C, Handsfield H,

Pequegnat W, Mayer K, Hartwell TD, Quinn TC. The incidence and
correlates of symptomatic and asymptomatic Chlamydia trachomatis and
Neisseria gonorrhoeae infections in selected populations in five countries.
Sex Transm Dis. 2011 Jun;38(6):503-9. [PMC free article] [PubMed]

Mabey D, Peeling RW. Lymphogranuloma venereum. Sex Transm Infect. 2002

Apr;78(2):90-2. [PMC free article] [PubMed]

Mordhorst CH, Dawson C. Sequelae of neonatal inclusion conjunctivitis and

 41

associated disease in parents. Am J Ophthalmol. 1971 Apr;71(4):861-7.

[PubMed]

Morré SA, Rozendaal L, van Valkengoed IG, Boeke AJ, van Voorst Vader PC,
Schirm J, de Blok S, van Den Hoek JA, van Doornum GJ, Meijer CJ, van
Den Brule AJ. Urogenital Chlamydia trachomatis serovars in men and
women with a symptomatic or asymptomatic infection: an association with
clinical manifestations? J Clin Microbiol. 2000 Jun;38(6):2292-6. [PMC
free article] [PubMed]

Pelvic inflammatory disease. Am Fam Physician. 2012 Apr 15;85(8):797-8.

[PubMed]

Professional, C. C. M. (n.d.). Botulism (Clostridium botulinum). Cleveland Clinic.

https://my.clevelandclinic.org/health/diseases/17828-botulism

Wusu-Edusei K, Chesson HW, Gift TL, Tao G, Mahajan R, Ocfemia MC, Kent
CK. The estimated direct medical cost of selected sexually transmitted infections
in the
United States, 2008. Sex Transm Dis. 2013 Mar;40(3):197-201. [PubMed]

Centers for Disease Control and Prevention (n.d). Causes, How it Spreads, &
People at Increased Risk. https://www.cdc.gov/legionella/about/causes-
transmission.html

World Health Organization (September 22). Legionellosis.

https://www.who.int/news-room/fact-sheets/detail/legionellosis

Centers for Disease Control and Prevention. (n.d.). Anthrax - Basics.

https://www.cdc.gov/anthrax/basics/index.html

Centers for Disease Control and Prevention. (n.d.). Anthrax - Types of Anthrax.
https://www.cdc.gov/anthrax/basics/types/index.html

Centers for Disease Control and Prevention. (n.d.). Anthrax - Treatment.

https://www.cdc.gov/anthrax/treatment/index.html

Mayo Clinic. (n.d.). Anthrax - Symptoms and Causes.

https://www.mayoclinic.org/diseases-conditions/anthrax/symptoms-
causes/syc-20356203

Mayo Clinic. (n.d.). Anthrax - Diagnosis and Treatment.

 42

https://www.mayoclinic.org/diseases-conditions/anthrax/diagnosis-
treatment/drc-20356209

Department of Health (DOH). (2021, April 1). DOH: Risk of anthrax infection
among ` general population 'very low'.
https://www.msn.com/en-ph/news/national/doh-risk-of-anthrax-infection-
among-general-population-very-low/ar-BB1kNRno

Centers for Disease Control and Prevention. (n.d.). Anthrax vaccine.

https://www.cdc.gov/anthrax/prevention/vaccine/index.html